<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879593</url>
  </required_header>
  <id_info>
    <org_study_id>ANTADIR PTcCO2/SLA</org_study_id>
    <nct_id>NCT00879593</nct_id>
  </id_info>
  <brief_title>Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Potential Role for Nocturnal PtcCO2 Monitoring in the Close Follow up of ALS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons,&#xD;
      with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS&#xD;
      and remains the main prognostic factor. Timing and rate of progression of this respiratory&#xD;
      muscle involvement is also highly variable among individuals.&#xD;
&#xD;
      Respiratory manifestations justify a careful follow up including clinical evaluation,&#xD;
      pulmonary function tests and blood gases. Prognostic value of respiratory muscle assessment&#xD;
      has been clearly demonstrated in ALS, although several cut off values have been published.&#xD;
      The clinical benefit of non invasive ventilation (NIV) is well established in ALS, but the&#xD;
      optimal criteria for its initiation remain debated .&#xD;
&#xD;
      The 1999 consensus for NIV selected classical criteria to consider NIV in patients with&#xD;
      respiratory symptoms suggesting hypoventilation: daytime hypercapnia (PaCO2 &gt; 45 mmHg),&#xD;
      nocturnal SaO2 &lt; 89 % more than 5 consecutive minutes and for progressive neuromuscular&#xD;
      disorders (NMD) (mainly ALS), a vital capacity (VC) &lt; 50 % pred or a PImax &lt; 60 cmH2O.&#xD;
&#xD;
      Besides daytime clinical and PFT assessment, nocturnal evaluation is essential in ALS. The&#xD;
      prevalence of sleep apnea ranges from 16 % to 76 %.&#xD;
&#xD;
      Transcutaneous PCO2 (tcPCO2) is an attractive technique to evaluate non invasively nocturnal&#xD;
      hypoventilation. The technique is well validated in different settings. Its use in&#xD;
      neuromuscular disorders (NMD) is recent. In particular one study has demonstrated a high&#xD;
      predictive value of tcPCO2 for the development of daytime hypoventilation within 1 year. To&#xD;
      our knowledge, this technique has not been specifically assessed in ALS. There is a potential&#xD;
      role for nocturnal PtcCO2 monitoring in the close follow up of ALS patients. Indeed, a close&#xD;
      respiratory follow up of ALS patients is essential to determine the optimal timing of NIV,&#xD;
      avoiding the occurence of unexpected acute respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal Transcutaneous PCO2</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>PtcCO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PtcCO2</intervention_name>
    <description>Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.</description>
    <arm_group_label>PtcCO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Amyotrophic lateral sclerosis :definite, probable or probable with EMG (Airlie House&#xD;
             Criteria, 1998).&#xD;
&#xD;
          -  Forced vital capacity &gt;70% pred.&#xD;
&#xD;
          -  Daytime PaCO2 &lt;43 mmHg.&#xD;
&#xD;
          -  Venous HCO3- &lt;28 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to perform pulmonary function tests or nocturnal recordings.&#xD;
&#xD;
          -  Coexisting significant lung disease: moderate to severe asthma or COPD&#xD;
&#xD;
          -  Current NIV, CPAP or oxygen therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry PEREZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU LILLE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PEREZ</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PÃ´le des maladies respiratoires et service EFR- Centre hospitalier Regional Universitaire</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</investigator_affiliation>
    <investigator_full_name>DELRIEU Jacqueline</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

